Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HIV/AIDS Vaccines
Findings from G. Pialoux and co-researchers advance knowledge in HIV/AIDS vaccines
June 25th, 2008
Fresh data on HIV/AIDS are presented in the report 'Phase I study of a candidate vaccine based on recombinant HIV-1 gp160 (MN/LAI) administered by the mucosal route to HIV-seronegative volunteers: the ANRS VAC14 study.' "One goal of HIV vaccination is to achieve high mucosal levels of specific secretory IgA (SIgA). In order to elicit specific SIgA antibodies against human immunodeficiency virus type-1 (HIV-1), a vaccine must be administered by the mucosal route, to the nasal or vaginal mucosa for example," researchers in France report. "We report here the results of the first phase I, randomized, open-label trial designed to assess the mucosal tolerability and...
Source: Vaccine Weekly (2008-06-25)
|
